The global prevalence and association between the risk of myocarditis and mRNA-based COVID-19 vaccination: A network meta-analysis
Open Access
- 29 July 2022
- journal article
- research article
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 862
Abstract
Background: Cases of myocarditis development have been reported after administration of messenger ribonucleic acid (mRNA)-based coronavirus disease (COVID-19) vaccines. However, the reports vary among the studies, and the types of mRNA vaccines with potential to cause myocarditis remain unidentified. The objective was to assess the cumulative prevalence of myocarditis and determine the association between myocarditis and mRNA-based COVID-19 vaccination. Methods: We performed a network meta-analysis by searching articles in PubMed, Scopus, and Web of Science. Information on the prevalence of myocarditis after the mRNA-based COVID-19 vaccination was collected from each study. Analysis was performed by calculating the pooled prevalence rate, and the association was determined using the Z-test. Data networking was performed using the Bayesian method. Results: A total of 18 papers was included in our analysis. We found that the cumulative prevalence of myocarditis was 1.7, 1.9, 1.2, and 1.1 per 100,000 population after vaccination with different types of mRNA-based COVID-19 vaccines, namely all mRNA COVID-19 vaccines, BNT162b1, mRNA-1273, and the combination of BNT162b1 and mRNA-1273, respectively. Moreover, the results revealed that BNT162b1 vaccination increased the risk of myocarditis by 1.64- and 1.71-folds compared to mRNA-1273 and the combination of BNT162b2 and mRNA-1273, respectively. Similar risks of developing myocarditis were observed after mRNA-1273 and the combination of BNT162b1 and mRNA-1273 vaccination. Conclusions: Our findings suggest the cumulative prevalence of myocarditis after mRNA-based COVID-19 vaccination with maximum prevalence was observed after BNT162b2 administration. BNT162b2 was associated with a higher risk of developing myocarditis than the other mRNA-based COVID-19 vaccines.Keywords
This publication has 50 references indexed in Scilit:
- Willingness-to-pay for a hypothetical Ebola vaccine in Indonesia: A cross-sectional study in AcehF1000Research, 2019
- Porphyromonas gingivalis vesicles reduce MDA-LDL levels and aortic wall thickness in high fat diet induced atherosclerosis ratsArtery Research, 2018
- Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trialThe Lancet, 2017
- Socioeconomic and Attitudinal Variables Associated with Acceptance and Willingness to Pay Towards Dengue Vaccine: A Systematic ReviewArchives of Clinical Infectious Diseases, 2017
- Community Willingness to Participate in a Dengue Study in Aceh Province, IndonesiaPLOS ONE, 2016
- MyocarditisDeutsches Ärzteblatt international, 2012
- Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitroJournal of Muscle Research and Cell Motility, 2012
- Molecular Mimicry as a Mechanism of Autoimmune DiseaseClinical Reviews in Allergy & Immunology, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- MyocarditisNew England Journal of Medicine, 2009